| 摘要 |
<p>Abstract A drug product comprising: a dry powder inhalation device having a pharmaceutical composition present therein, said pharmaceutical composition 5 comprising a compound which is (6a, 11B, 16a, 17 a)-6,9-difluoro-17 {[(fluoromethyl)thio]carbonyl}- 11 -hydroxy-16-methyl-3-oxoandrosta-1, 4-dien-17 -yl 2- furancarboxylate and lactose, said drug product further comprising: (1) silica gel, wherein the silica gel is present in a state of partial hydration and having a moisture content ranging from 8.4 % w/w to 18.6 % w/w and (2) a package which 10 encompasses the dry powder inhalation device and the silica gel defining an enclosed volume therein, wherein the enclosed volume exhibits a Relative Humidity of from 20% to 40%.</p> |
